Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Metlife (MET-PA) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Metlife (MET-PA) over the last 17 years, with Q3 2025 value amounting to $280.0 million.

  • Metlife's Receivables - Net rose 1428.57% to $280.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $280.0 million, marking a year-over-year increase of 1428.57%. This contributed to the annual value of $29.8 billion for FY2024, which is 272.69% up from last year.
  • Latest data reveals that Metlife reported Receivables - Net of $280.0 million as of Q3 2025, which was up 1428.57% from $265.0 million recorded in Q2 2025.
  • In the past 5 years, Metlife's Receivables - Net registered a high of $31.3 billion during Q1 2025, and its lowest value of $231.0 million during Q2 2024.
  • For the 5-year period, Metlife's Receivables - Net averaged around $15.9 billion, with its median value being $17.9 billion (2022).
  • In the last 5 years, Metlife's Receivables - Net surged by 775169.49% in 2023 and then tumbled by 9875.34% in 2024.
  • Metlife's Receivables - Net (Quarter) stood at $17.1 billion in 2021, then grew by 1.25% to $17.4 billion in 2022, then skyrocketed by 66.85% to $29.0 billion in 2023, then grew by 2.73% to $29.8 billion in 2024, then tumbled by 99.06% to $280.0 million in 2025.
  • Its last three reported values are $280.0 million in Q3 2025, $265.0 million for Q2 2025, and $31.3 billion during Q1 2025.